Open-label long-term belimumab extension in ILD associated with systemic sclerosis and other connective tissue diseases

Open-label, single-arm trial of belimumab in pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD) and connective tissue disease-associated interstitial lung disease (CTD-ILD), sponsored by GSK. Primary endpoint: Number of participants with adverse events (AEs), adverse events of special interest (AESIs), and serious adverse events (SAEs). Started May 2025; status: recruiting.